Plain-English translation of NCT05856851 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether , a clot-dissolving medication given directly into blood vessels, improves recovery when added after emergency mechanical thrombectomy (a procedure that removes blood clots from the brain during acute stroke). About half of participants will receive the medication after their thrombectomy, while the other half will receive standard care alone. Researchers will compare how well each group recovers over 90 days.
After emergency stroke treatment, some patients still have incomplete blood flow to the brain. This medication might help dissolve remaining clots and improve blood flow, potentially leading to better outcomes—but doctors need to study whether it's truly helpful and safe.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to receive either the experimental medication or standard care after your thrombectomy procedure. If assigned to the medication group, you will receive a 15-minute infusion of directly into your brain's blood vessels, followed by imaging to check how the clot is dissolving. All participants will receive standard stroke care and follow-up visits, with the main assessment happening at 90 days after your stroke to evaluate your recovery and independence.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China